In our CRC cohort, the CMS1 subtype—which is characterized by an MSI-high, immune phenotype20—had the highest TACSTD2 expression, which was in turn associated with more immune infiltration and higher prevalence of T-cell inflamed tumors. Here, TACSTD2 is linked to colorectal carcinoma.